Description

FDA Approval:FDA First approved onJanuary 8, 2014Brand name: FarxigaGeneric name: Dapagliflozin Dosage form: Tablets OralCompany: AstraZenecaTreatment for: Diabetes, Type 2, Renal Failure, Heart FailureFarxiga (Dapagliflozin) is a sodium -glucose cotransporter 2 (SGLT2) inhibitor indicated for the treatment of Type II diabetes mellitus, heart failure, and chronic kidney disease.Developmental timeline for Farxia(Dapaglidflozin):-•April 30, 2021 Approval: Farxiga approved in the US for the Treatment of Chronic Kidney Disease in patients at risk of progression with and without ithout Type-2 Diabetes.•May 6, 2020 Approval Farxiga Approved in the US for the treatment of Heart Failure in patients with Heart Failure with reduced ejection